Swiss biopharma company Relief Therapeutics publishes 2023 Annual Report, highlighting progress on rare disease treatments RLF-TD011 and RLF-OD032.
Relief Therapeutics, a Swiss biopharma company, has published its 2023 Annual Report. Focused on rare and unmet diseases, the company emphasizes optimizing operations and accelerating priority programs. Relief is excited about potential treatments like RLF-TD011 for epidermolysis bullosa and RLF-OD032 for phenylketonuria. The company is headquartered in Geneva and listed on the SIX Swiss Exchange.
April 30, 2024
4 Articles